Journal of Cardiac Failure最新文献

{"title":"Prognostic Implications of Quantifying Vasoactive Medications in Cardiogenic Shock","authors":"SARASCHANDRA VALLABHAJOSYULA MD, MSC , ANTHONY J. FAUGNO MD , BORUI LI MA , KEVIN JOHN MD , QIUYUE KONG MA , SHASHANK S. SINHA MD, MSC , JAIME HERNANDEZ-MONTFORT MD , MANREET K. KANWAR MD , JACOB ABRAHAM MD , VANESSA BLUMER MD , MARYJANE FARR MD, MSC , JUSTIN FRIED MD , ARTHUR R. GARAN MD , SHELLEY HALL MD , GAVIN W. HICKEY MD , RACHNA KATARIA MD , JU KIM MD , SONG LI MD , CLAUDIUS MAHR MD , SANDEEP NATHAN MD, MSC , NAVIN K. KAPUR MD","doi":"10.1016/j.cardfail.2024.06.010","DOIUrl":"10.1016/j.cardfail.2024.06.010","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 11","pages":"Pages 1516-1521"},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Medical Necessity Isn't Persuasive Enough: Utilizing Patient Social Media Support Communities To Induce Acceptance Of Cardiac ProceduresA Study In Social Media's Role in Implanted Cardiac Device Acceptance","authors":"","doi":"10.1016/j.cardfail.2024.10.433","DOIUrl":"10.1016/j.cardfail.2024.10.433","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 11","pages":"Pages 1539-1541"},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142650909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4","authors":"AHMAD MASRI MD, MS ,&nbsp;MARK V. SHERRID MD ,&nbsp;THEODORE P. ABRAHAM MD ,&nbsp;LUBNA CHOUDHURY MD, MRCPI ,&nbsp;PABLO GARCIA-PAVIA MD, PhD ,&nbsp;CHRISTOPHER M. KRAMER MRCPI ,&nbsp;ROBERTO BARRIALES-VILLA MD, PhD ,&nbsp;ANJALI T. OWENS MD ,&nbsp;FLORIAN RADER MD ,&nbsp;SHERIF F. NAGUEH MD ,&nbsp;IACOPO OLIVOTTO MD ,&nbsp;SARA SABERI MD ,&nbsp;ALBREE TOWER-RADER MD ,&nbsp;TIMOTHY C. WONG MD ,&nbsp;CAROLINE J. COATS MD, PhD ,&nbsp;HUGH WATKINS MD, PhD ,&nbsp;MICHAEL A. FIFER MD ,&nbsp;SCOTT D. SOLOMON MD ,&nbsp;STEPHEN B. HEITNER MD ,&nbsp;DANIEL L. JACOBY MD ,&nbsp;MARTIN S. MARON MD","doi":"10.1016/j.cardfail.2024.02.020","DOIUrl":"10.1016/j.cardfail.2024.02.020","url":null,"abstract":"<div><h3>Background</h3><div>This open-label phase 2 trial evaluated the safety and efficacy of aficamten in patients with nonobstructive hypertrophic cardiomyopathy (nHCM).</div></div><div><h3>Methods</h3><div>Patients with symptomatic nHCM (left ventricular outflow tract obstruction gradient ≤ 30 mmHg, left ventricular ejection fraction [LVEF] ≥ 60%, N-terminal pro-B-type natriuretic peptide [NT-proBNP] &gt; 300 pg/mL) received aficamten 5–15 mg once daily (doses adjusted according to echocardiographic LVEF) for 10 weeks.</div></div><div><h3>Results</h3><div>We enrolled 41 patients (mean ± SD age 56 ± 16 years; 59% female). At Week 10, 22 (55%) patients experienced an improvement of ≥ 1 New York Heart Association class; 11 (29%) became asymptomatic. Clinically relevant improvements in Kansas City Cardiomyopathy Questionnaire Clinical Summary Scores occurred in 22 (55%) patients. Symptom relief was paralleled by reductions in NT-proBNP levels (56%; <em>P</em> &lt; 0.001) and high-sensitivity cardiac troponin I (22%; <em>P</em> &lt; 0.005). Modest reductions in LVEF (mean ± SD) of −5.4% ± 10 to 64.6% ± 9.1 were observed. Three (8%) patients had asymptomatic reduction in LVEF &lt; 50% (range: 41%–48%), all returning to normal after 2 weeks of washout. One patient with prior history of aborted sudden cardiac death experienced a fatal arrhythmia during the study.</div></div><div><h3>Conclusions</h3><div>Aficamten administration for symptomatic nHCM was generally safe and was associated with improvements in heart failure symptoms and cardiac biomarkers.</div></div><div><h3>Trial registration</h3><div>ClinicalTrials.gov Identifier: NCT04219826</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 11","pages":"Pages 1439-1448"},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low Levels of Selenoprotein P Are Associated With Cognitive Impairment in Patients Hospitalized for Heart Failure","authors":"Amra Jujić PhD ,&nbsp;John Molvin PhD ,&nbsp;Erik D. Nilsson PhD ,&nbsp;Hannes Holm Isholth PhD ,&nbsp;Anna Dieden MSc ,&nbsp;Johan Korduner PhD ,&nbsp;Amir Zaghi MD ,&nbsp;Zainu Nezami MD ,&nbsp;Andreas Bergmann PhD ,&nbsp;Lutz Schomburg PhD ,&nbsp;Martin Magnusson PhD","doi":"10.1016/j.cardfail.2024.01.010","DOIUrl":"10.1016/j.cardfail.2024.01.010","url":null,"abstract":"<div><h3>Background</h3><div>Selenoprotein P (SELENOP) is a transporter for selenium and has been shown to protect selenium-status maintenance in the brain against deficiency and to support neuronal development, neurogenesis and neurocognitive function. Selenium deficiency has previously been associated with cognitive impairment in various populations, but no studies have been carried out in subjects with heart failure (HF).</div></div><div><h3>Purpose</h3><div>To explore whether SELENOP deficiency in subjects with acute HF is associated with cognitive impairment.</div></div><div><h3>Methods</h3><div>Plasma SELENOP, as measured by an immunoassay analysis, is a well-validated marker of plasma selenium status and has the benefit of providing information on the bioavailable fraction of selenium to preferentially supplied cells equipped with receptors for SELENOP uptake. SELENOP was measured in 320 subjects hospitalized for HF. Of the subjects, 187 also underwent 4 cognitive tests assessing global cognitive function: Montreal Cognitive Assessment (MoCA); information processing (Symbol Digit Modalities Test [SDMT]); visual attention and task switching (Trailmaking Test A [TMT-A]); and executive speed (A Quick Test of Cognitive Speed [AQT] form and color). Appropriate cutoffs were used for each cognitive test to define cognitive impairment. Cross-sectional associations between SELENOP concentrations and cognitive impairment, as defined by each cognitive test, were explored using multivariable logistic models. Further, multivariable logistic models exploring associations between selenium deficiency, defined as the lowest quartile of SELENOP levels, and cognitive impairment, defined by each cognitive test, were carried out.</div></div><div><h3>Results</h3><div>The 187 participants had a mean age of 73 (± 11.9) years; 31% were female and had a mean body mass index of 28.1 (± 5.6) kg/m². Each 1 standard deviation increment in SELENOP concentrations was associated with lower odds of cognitive impairment, defined as a MoCA cut-off score &lt; 23 (odds ratio [OR] 0.60; 95% CI 0.40–0.91; <em>P</em> = 0.017). Further, SELENOP concentrations in the lowest quartile (≤ 2.3 mg/L) were associated with cognitive impairment as measured by MoCA (OR 3.10; 95% CI 1.38–6.97; <em>P</em> = 0.006), SDMT (OR 2.26; 95% CI 1.10–4.67; <em>P</em> = 0.027) and TMT-A (OR 3.40; 95% CI 1.47–7.88; <em>P</em> = 0.004) but not by AQT form and color.</div></div><div><h3>Conclusions</h3><div>In subjects admitted for HF, higher SELENOP concentrations were associated with better performance on the MoCA test, reflecting global cognition, and SELENOP deficiency was associated with cognitive impairment as defined by 3 cognitive tests.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 11","pages":"Pages 1452-1461"},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139746701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Implantable Cardioverter-defibrillators in Nonischemic Heart Failure According to Background Medical Therapy: Extended Follow-up of the DANISH Trial","authors":"ADELINA YAFASOVA MD ,&nbsp;SEIKO N. DOI MD, PhD ,&nbsp;JENS JAKOB THUNE MD, PhD ,&nbsp;JENS C. NIELSEN MD, DMSc ,&nbsp;JENS HAARBO MD, DMSc ,&nbsp;NIELS E. BRUUN MD, DMSc ,&nbsp;FINN GUSTAFSSON MD, DMSc ,&nbsp;HANS EISKJÆR MD, DMSc ,&nbsp;CHRISTIAN HASSAGER MD, DMSc ,&nbsp;JESPER H. SVENDSEN MD, DMSc ,&nbsp;DAN E. HØFSTEN MD, PhD ,&nbsp;CHRISTIAN TORP-PEDERSEN MD, DMSc ,&nbsp;STEEN PEHRSON MD, DMSc ,&nbsp;LARS KØBER MD, DMSc ,&nbsp;JAWAD H. BUTT MD","doi":"10.1016/j.cardfail.2024.04.017","DOIUrl":"10.1016/j.cardfail.2024.04.017","url":null,"abstract":"<div><h3>Background</h3><div>The Heart Failure Collaboratory (HFC) score integrates types and dosages of guideline-directed pharmacotherapies for heart failure (HF) with reduced ejection fraction (HFrEF). We examined the effects of cardioverter-defibrillator (ICD) implantation according to the modified HFC (mHFC) score in 1116 patients with nonischemic HFrEF from the Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic HF on Mortality (DANISH).</div></div><div><h3>Methods and Results</h3><div>Patients were assigned scores for renin-angiotensin-system inhibitors, beta-blockers and mineralocorticoid receptor antagonists (0, no use; 1, &lt; 50% of maximum dosage; 2, ≥ 50% of maximum dosage). The maximum score was 6, corresponding to ≥ 50% of maximum dosage for all therapies. The median baseline mHFC score was 4, and the median follow-up was 9.5 years. Compared with an mHFC score of 3–4, an mHFC score of 1–2 was associated with a higher rate of all-cause death (mHFC = 1–2: adjusted HR 1.67 [95% CI, 1.23–2.28]; mHFC = 3–4, reference; mHFC = 5–6: adjusted HR 1.07 [95% CI, 0.87–1.31]). ICD implantation did not reduce all-cause death compared with control (reference) (HR 0.89 [95% CI, 0.74–1.08]), regardless of mHFC score (mHFC = 1–2: HR 0.98 [95% CI, 0.56–1.71]; mHFC = 3-4: HR 0.89 [95% CI,0.66–1.20]; mHFC = 5–6: HR 0.85 [95% CI, 0.64–1.12]; <em>P</em>_interaction, 0.65). Similarly, ICD implantation did not reduce cardiovascular death (HR 0.87 [95% CI, 0.70–1.09]), regardless of mHFC score (<em>P</em>_interaction, 0.59). The ICD group had a lower rate of sudden cardiovascular death (HR, 0.60 [95% CI,0.40–0.92]); this association was not modified by mHFC score (<em>P</em>_interaction, 0.35).</div></div><div><h3>Conclusions</h3><div>Lower mHFC scores were associated with higher rates of all-cause death. ICD implantation did not result in an overall survival benefit in patients with nonischemic HFrEF, regardless of mHFC score.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 11","pages":"Pages 1411-1420"},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association Between Preoperative Pectoralis Muscle Quantity and Outcomes After Cardiac Transplantation","authors":"ELISSA DRIGGIN MD, MS ,&nbsp;ALICE CHUNG MD ,&nbsp;ERIN HARRIS MD ,&nbsp;ABRAHAM BORDON MD ,&nbsp;SALWA RAHMAN MD ,&nbsp;GABRIEL SAYER MD ,&nbsp;KOJI TAKEDA MD ,&nbsp;NIR URIEL MD, MS ,&nbsp;MATHEW S. MAURER MD ,&nbsp;JAY LEB MD ,&nbsp;KEVIN CLERKIN MD, MS","doi":"10.1016/j.cardfail.2024.03.012","DOIUrl":"10.1016/j.cardfail.2024.03.012","url":null,"abstract":"<div><h3>Background</h3><div>Sarcopenia<span><span> is underappreciated in advanced heart failure and is not routinely assessed. In patients receiving a left ventricular assist device, preoperative sarcopenia, defined by using computed-tomography (CT)-derived pectoralis muscle-area index (muscle area indexed to body-surface area), is an independent predictor of </span>postoperative mortality<span>. The association between preoperative sarcopenia and outcomes after heart transplant (HT) is unknown.</span></span></div></div><div><h3>Objectives</h3><div>The primary aim of this study was to determine whether preoperative sarcopenia, diagnosed using the pectoralis muscle-area index, is an independent predictor of days alive and out of the hospital (DAOHs) post-transplant.</div></div><div><h3>Methods</h3><div>Patients who underwent HT between January, 2018, and June, 2022, with available preoperative chest CT scans were included. Sarcopenia was diagnosed as pectoralis muscle-area index in the lowest sex-specific tertile. The primary endpoint was DAOHs at 1 year post-transplant.</div></div><div><h3>Results</h3><div>The study included 169 patients. Patients with sarcopenia (n = 55) had fewer DAOHs compared to those without sarcopenia, with a median difference of 17 days (320 vs 337 days; <em>P</em> = 0.004). Patients with sarcopenia had longer index hospitalizations and were also more likely to be discharged to a facility other than home. In a Poisson regression model, sarcopenia was a significant univariable and the strongest multivariable predictor of DAOHs at 1 year (parameter estimate = -0.17, 95% CI -0.19 to -14; <em>P</em> = &lt; 0.0001).</div></div><div><h3>Conclusions</h3><div>Preoperative sarcopenia, diagnosed using the pectoralis muscle-area index, is an independent predictor of poor outcomes after HT. This parameter is easily measurable from commonly obtained preoperative CT scans and may be considered in transplant evaluations.</div></div>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 11","pages":"Pages 1462-1468"},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140770167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ivabradine in Cardiogenic Shock","authors":"Maya Guglin MD, PhD","doi":"10.1016/j.cardfail.2024.05.015","DOIUrl":"10.1016/j.cardfail.2024.05.015","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":"30 11","pages":"Pages 1504-1506"},"PeriodicalIF":6.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter to the Editor: Regarding: the Power in Our Patients' Hands: Exploring LVAD and Suicide.","authors":"Quentin R Youmans, Christine Yu Moutier, Kathy Neely, Alyssa M Vela, Eren Youmans Watkins, Anjan Tibrewala","doi":"10.1016/j.cardfail.2024.10.436","DOIUrl":"10.1016/j.cardfail.2024.10.436","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Regarding \"The Power in Our Patients' Hands: Exploring LVAD and Suicide\".","authors":"Christopher E Knoepke, Abigail L Latimer, Ian H Stanley, Grant Yoder, Prateeti Khazanie","doi":"10.1016/j.cardfail.2024.09.020","DOIUrl":"10.1016/j.cardfail.2024.09.020","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Machine Learning Derived Risk Score Improves Prediction of Outcomes Post-LVAD Implantation: An Analysis of the INTERMACS database.","authors":"Jin Joo Park, Sonya John, Claudio Campagnari, Avi Yagil, Barry Greenberg, Eric Adler","doi":"10.1016/j.cardfail.2024.09.013","DOIUrl":"https://doi.org/10.1016/j.cardfail.2024.09.013","url":null,"abstract":"<p><strong>Background: </strong>Significant variability in post-left ventricular assist device (LVAD) implantation outcomes emphasize the importance of accurately assessing patients' risk prior to surgery. This study assesses the MARKER-HF mortality risk model, a machine learning-based tool utilizing 8 clinical variables, to predict post-LVAD implantation mortality and its prognostic enhancement over the INTERMACS profile.</p><p><strong>Methods: </strong>Analyzing 25,365 INTERMACS database patients (mean age 56.8 years, 78% male), 5,663 (22.3%) and 19,702 (77.7%) received HeartMate 3 and other types of LVAD. They were categorized into low, moderate, high, and very high-risk groups based on MARKER-HF score. The outcomes of interest were in-hospital and 1-year post-discharge mortality.</p><p><strong>Results: </strong>In patients receiving HM3 devices, 6.2% died during index hospitalization. In-hospital mortality progressively increased from 4.4% in low to 15.2% in very high -risk groups with MARKER-HF score. MARKER-HF provided additional risk discrimination within each INTERMACS profile. Combining MARKER-HF score and INTERMACS profile identified patients with the lowest (3.5%) and highest in-hospital mortality (19.8%) rates. Post-discharge mortality rate at one year was 5.8% in this population. In a Cox-proportional hazard regression analysis adjusting for both MARKER-HF and INTERMACS profile, only MARKER-HF score (hazard ratio: 1.27, 95% CI: 1.11-1.46, P<0.001) was associated with post-discharge mortality. Similar findings were observed for patients receiving other types of LVAD.</p><p><strong>Conclusions: </strong>The MARKER-HF score is a valuable tool for assessing mortality risk in HF patients undergoing HM3 and other LVAD implantation. It offers prognostic information beyond that of the INTERMACS profile alone and it's use should help in the shared decision-making process for LVAD implantation.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}